hydrazine has been researched along with Anemia, Aplastic in 98 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.02) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 53 (54.08) | 24.3611 |
2020's | 44 (44.90) | 2.80 |
Authors | Studies |
---|---|
Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Quinones Raffo, D; Rios, O; Shalhoub, R; Wu, CO; Young, NS | 1 |
Angelucci, E; Barcellini, W; Barraco, F; Cacace, F; Cavenagh, J; Clement, L; Cook, R; Daguindau, E; de Groot, MR; Drexler, B; Dufour, C; Forcade, E; Frieri, C; Griffin, M; Halkes, CJM; Hill, A; Iacobelli, S; Iori, AP; Jarque, I; Kulasekararaj, A; La Rocca, U; Marano, L; Marotta, S; Marsh, JCW; Mear, JB; Mufti, GJ; Munir, T; Muus, P; Nur, E; Palmisani, E; Passweg, JR; Peffault de Latour, R; Praire, A; Rabian, F; Raymakers, RAP; Recher, C; Risitano, AM; Russell, NH; Sánchez-Ortega, I; Sicre de Fontbrune, F; Smith, AE; Socié, G; Sureda, A; Tavitian, S; Terriou, L; Terwel, SR; Tjon, JML; Vallejo, JC; van Lint, MT; Xicoy, B | 1 |
Li, MJ; Liu, XJ; Song, YP; Wei, XD; Xiong, YY; Yuan, FF; Zhang, LN; Zhang, QL; Zhou, H | 1 |
Grabowski, DR; Guan, Y; Hasipek, M; Jha, BK; Jiang, D; Kongkiatkamon, S; LaFramboise, T; Lindner, D; Maciejewski, JP; Mian, OY; Pagliuca, S; Parker, Y; Patel, B; Saunthararajah, Y; Sekeres, MA; Singh, S; Tiwari, AD | 1 |
Eguchi, H; Eguchi, K; Ishimura, M; Kakiuchi, T; Koga, D; Matsuo, M; Nishi, M; Sonoda, M | 1 |
Calvo, KR; Desmond, R; Dunbar, CE; Fan, X; Groarke, EM; Larochelle, A; Patel, B; Winkler, T; Young, DJ; Young, NS | 1 |
Chen, Y; Huang, F; Li, JY; Qiao, C; Shen, WY; Wang, R; Wang, Y; Zha, Q | 1 |
Horiuchi, T; Izumi, T; Kawamura, T; Kimura, F; Kobayashi, S; Sato, K; Takano, K | 1 |
Chan, FHY; Chan, KP; Chan, TSY; Hwang, YY; Kho, B; Kwong, YL; Lau, CK; Lau, CWP; Lau, GWN; Lau, JSM; Leung, KH; Lin, SY; Luk, YY; Mak, V; Sim, JPY; Yip, SF | 1 |
He, GS; Huang, LF; Jia, JS; Li, L; Lin, SY; Meng, FK; Yang, Y; Zhang, DH | 1 |
Arita, K; Hosono, N; Imi, T; Iwaki, N; Murakami, J; Nakao, S; Nannya, Y; Ogawa, S; Okazawa, H; Tasaki, T; Tsujikawa, T | 1 |
Chen, M; Han, B; Liu, B; Zhang, B; Zuo, W | 1 |
Fu, R; Han, B; Jiao, W; Lei, M; Liu, L; Liu, R; Miao, M; Wu, D; Zhang, F; Zhang, L; Zhang, Y; Zhao, X | 1 |
He, G; Jia, J; Jin, Y; Li, J; Li, R; Lin, S; Yang, Y; Zhang, D | 1 |
Barth, D; Benitez, LL; Bixby, D; Buhlinger, KM; Burke, P; Desai, R; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH; Shinn, LT; Soule, A; Stump, SE; van Deventer, H; Wagner, CB; Weis, TM; Zacholski, K | 1 |
Chang, H; Fu, R; Han, B; He, G; Jin, H; Li, F; Li, T; Liu, L; Mittal, H; Zhang, F | 1 |
Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G | 1 |
Arcona, S; Cai, B; Li, FY; Li, X; Said, Q | 1 |
Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S | 1 |
Antin, J; Bilginsoy, M; Duh, MS; Huynh, L; Ivanova, JI; Peffault de Latour, R; Roy, A; Totev, T | 1 |
Gao, Q; Guan, D; Hu, J; Liu, X; Zhang, F; Zhu, Y | 1 |
Alemu, L; Feng, X; Groarke, EM; Kajigaya, S; Patel, BA; Quinones Raffo, D; Young, NS; Zaimoku, Y | 1 |
Albitar, M; Barranta, ME; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Fan, X; Gutierrez-Rodrigues, F; Lotter, J; Sellers, SE; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, CO; Young, DJ; Young, NS | 1 |
Hangaishi, A; Hirao, M; Iizuka, H; Kamoda, Y; Kida, M; Uchibori, Y; Usuki, K | 1 |
Cheng, H; Wang, X; Xu, KL | 1 |
Babushok, DV; Sun, L | 1 |
Avgerinou, G; Filippidou, M; Katsibardi, K; Kattamis, A; Roka, K; Solomou, E; Tourkantoni, N; Tsipou, H; Vlachou, A | 1 |
Hosokawa, K; Imi, T; Nakao, S; Sugimori, N; Tanabe, M; Yamazaki, H | 1 |
Al-Samkari, H; Goodarzi, K | 1 |
Hirao, M; Iizuka, H; Ise, M; Kamoda, Y; Kida, M; Usuki, K | 1 |
Chen, M; Han, B; Ruan, J; Yang, C; Zuo, W | 1 |
Babushok, D; Bagg, A; Hurwitz, SN; Juusola, J; Sklarz, T; Stanley, NL | 1 |
Calado, RT; Catto, LFB; Quintino de Oliveira, B; Santana, BAA; Scheinberg, P; Scheucher, PS; Tellechea, MF | 1 |
Fanghong, Z; Hombo, Y; Iida, H; Imada, K; Imajo, K; Kumagai, A; Maeda, T; Matsuda, A; Nakao, S; Obara, N; Tajima, T; Usuki, K | 1 |
Olson, TS | 1 |
Baldoni, D; Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Rios, O; Shalhoub, R; St Pierre, A; Townsley, DM; Wu, CO; Young, NS | 1 |
Chiu, V; Hermel, D; Martynova, A; Mert, M; Weitz, IC | 1 |
Cheng, X; Fu, L; He, Y; Jie, M; Li, S; Wu, R; Yao, J; Zhang, L; Zhang, R; Zheng, J | 1 |
Scheinberg, P | 4 |
Boals, M; Ding, J; Gray, N; Hale, M; Jacobs, T; Kang, G; Lesmana, H; Lewis, S; Reiss, U; Wang, W; Weiss, M; Wlodarski, M | 1 |
Feng, X; Groarke, EM; Patel, BA; Shalhoub, R; Wu, CO; Young, NS; Zaimoku, Y | 1 |
Chen, L; Han, S; Liu, J; Peng, Y; Wang, H; Wu, Y; Zhang, J | 1 |
Huan Ng, C; Jang-Milligan, F; Schultz, KR | 1 |
Chang, HH; Chou, SW; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Su, MY; Yang, YL | 1 |
Bevans, M; Calvo, KR; Desierto, M; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Larochelle, A; Leuva, H; Lotter, J; Rios, O; Scheinberg, P; Townsley, DM; Valdez, J; Weinstein, B; Winkler, T; Wu, C; Young, NS | 1 |
Bonfim, C; George, B; Kumar, R | 1 |
Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Olnes, M; Townsley, DM; Winkler, T; Wu, Z; Young, NS; Zhao, X | 1 |
Abraham, J; Ades, L; Balsat, M; Berceanu, A; Chaoui, D; Coppo, P; Corm, S; de Fontbrune, FS; de Latour, RP; Drenou, B; Dupriez, B; Guillerm, G; Leblanc, T; Lengline, E; Maillard, N; Peterlin, P; Raffoux, E; Socié, G; Terriou, L; Tournilhac, O | 1 |
Chan, TSY; Cheung, CYM; Gill, H; Hwang, YY; Kwong, YL; Leung, GMK | 1 |
Adam, S; Alharthi, S; Anyfantis, G; Armstrong, L; Barta, T; El-Harouni, AA; Elango, R; Gassner, K; Lako, M; Melguizo-Sanchis, D; Przyborski, S; Samarasinghe, S; Saretzki, G; Taheem, D; Tilgner, K; Wan, T; Xu, Y; Yu, M | 1 |
Gilreath, JA; Rodgers, GM | 1 |
Cheng, Z; Dunbar, CE; Grasmeder, S; Sokoll, LJ; Streiff, M; Sun, Q; Townsley, DM; Winkler, T; Young, NS; Zhao, Z | 1 |
Lázaro Rodríguez, I; Pérez Alonso, V; Rubio-San-Simón, A; Vázquez Gómez, F; Vivanco Martínez, JL | 1 |
Geng, W; Kearney, S; Nelson, S | 1 |
Gilreath, JA; Kurtti, AL; Rodgers, GM | 1 |
Fu, L; Li, S; Ma, J; Qin, M; Wang, B; Wu, R; Zhang, L; Zhou, X; Zhu, G | 1 |
Alvarado, Y; Assi, R; Borthakur, G; Burger, J; Cortes, J; Daver, NG; Dinardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Hendrickson, S; Jabbour, E; Kadia, TM; Kantarjian, H; Ravandi, F; Wierda, W | 1 |
Biancotto, A; Candia, J; Cheung, F; Fantoni, G; Feng, X; Giudice, V; Kajigaya, S; Rios, O; Townsley, D; Wu, Z; Young, NS | 1 |
Young, NS | 1 |
Chen, Y; Hong, Y; Li, N; Li, X; Wan, B | 1 |
Arnold, L; Barcellini, W; Benson-Quarm, N; Consonni, D; De Lavallade, H; Fattizzo, B; Griffin, M; Hill, A; Hillmen, P; Ireland, R; Kulasekararaj, AG; Marsh, JCW; Mufti, GJ; Munir, T; Potter, V; Riley, K | 1 |
Cao, J; Cheng, H; Larochelle, A; Wang, X; Xu, KL; Zhou, D | 1 |
Afanasyev, B; Bonifazi, F; Bosman, P; Bruno, B; Cortelezzi, A; de Latour, RP; Dreger, P; Drénou, B; Drexler, B; Dufour, C; Ecsedi, M; Eikema, DJ; Garnier, A; Giammarco, S; Halkes, CJM; Knol-Bout, C; Lanino, E; Lengline, É; Ljungman, P; Maschan, A; Onofrillo, D; Passweg, J; Patriarca, A; Pioltelli, P; Pulanic, D; Risitano, AM; Rovó, A; Serventi-Seiwerth, R; Tournilhac, O | 1 |
Ames, NJ; Barb, JJ; Cashion, AK; Childs, R; Faller, LL; Kim, H; Mudra, SE; Paster, BJ; Ranucci, A; Townsley, DM; Wallen, GR | 1 |
Calvo, KR; Cooper, J; Desierto, M; Desmond, R; Dunbar, CE; Fan, X; Grasmeder, S; Larochelle, A; Lotter, J; Scheinberg, P; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, C; Young, DJ; Young, NS | 1 |
Atay, H; Kelkitli, E; Turgut, M | 1 |
Arman Bilir, Ö; Işık, M; Kaçar, D; Özbek, NY; Yaralı, HN; Yazal Erdem, A | 1 |
Barcellini, W; Cavallaro, F; Fattizzo, B; Milesi, G | 1 |
Fanghong, Z; Hattori, T; Iida, H; Imada, K; Imajo, K; Matsuda, A; Miyamura, K; Nakao, S; Obara, N; Ohta, K; Sasaki, O; Tajima, T; Tokumine, Y; Tomiyama, Y; Usuki, K; Yamazaki, H | 1 |
Babushok, DV | 1 |
Barcellini, W; Cassin, R; Fattizzo, B; Levati, G | 1 |
Kulasekararaj, AG; Marsh, JC | 1 |
Bevans, M; Broder, K; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Olnes, MJ; Parikh, AR; Scheinberg, P; Townsley, DM; Wu, CO; Young, NS | 1 |
Nakao, S | 2 |
Marsh, JC; Mufti, GJ | 1 |
Bryan, J; Kadia, TM; Rexwinkle, A; Willis, L | 1 |
Bart-Smith, EE; Kordasti, S; Kulasekararaj, AG; Marsh, JC; Mufti, GJ; Richardson, D | 1 |
Höchsmann, B; Körper, S; Schrezenmeier, H | 1 |
Desmond, R; Dunbar, C; Townsley, DM; Young, NS | 1 |
McCormack, PL | 1 |
Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
Gounden, V; Zhao, Z | 1 |
John, JM; Malhotra, P | 1 |
Bown, N; Cavenagh, J; Dokal, I; Foukaneli, T; Hill, A; Hillmen, P; Ireland, R; Killick, SB; Kulasekararaj, A; Marsh, JC; Mufti, G; Samarasinghe, S; Snowden, JA; Wood, A | 1 |
Häckel, A | 1 |
Gill, H; Kwong, YL; Leung, GM; Lopes, D | 1 |
Kazemi, T; Martin, S; Worswick, S | 1 |
Grainger, JD; Lum, SH | 1 |
Townsley, DM; Winkler, T | 1 |
Biancotto, A; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Lozier, J; Olnes, MJ; Parikh, AR; Scheinberg, P; Soto, S; Tang, Y; Wu, CO; Young, NS | 1 |
Metcalf, D | 1 |
Oshima, Y; Tojo, A; Yuji, K | 1 |
Akard, L | 1 |
Akoun, G; Brocard, H | 1 |
22 review(s) available for hydrazine and Anemia, Aplastic
Article | Year |
---|---|
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles | 2020 |
Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis.
Topics: Anemia, Aplastic; Animals; Benzoates; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Transplantation, Homologous | 2020 |
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries.
Topics: Anemia, Aplastic; Animals; Benzoates; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Severity of Illness Index | 2021 |
A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles; Treatment Outcome | 2021 |
Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Topics: Allografts; Anemia, Aplastic; Benzoates; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles | 2021 |
Hematopoietic cell transplantation for aplastic anemia.
Topics: Allografts; Anemia, Aplastic; Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Practice Guidelines as Topic; Pyrazoles | 2017 |
Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Recurrence; Treatment Outcome | 2018 |
Aplastic Anemia.
Topics: Adult; Algorithms; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Transplantation, Homologous | 2018 |
Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2019 |
Activity of eltrombopag in severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Blood Cell Count; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Activity of eltrombopag in severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Disease-Free Survival; Humans; Hydrazines; Pyrazoles; Severity of Illness Index; Survival Rate | 2018 |
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2019 |
Management of the refractory aplastic anemia patient: what are the options?
Topics: Adult; Age Factors; Alemtuzumab; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Benzoates; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cyclosporine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Siblings; Survival Rate; Unrelated Donors | 2013 |
[Recent issues and prospects of the treatment of aplastic anemia].
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Biomarkers; Cyclosporine; Drug Therapy, Combination; Herpesvirus 4, Human; Humans; Hydrazines; Immunosuppressive Agents; Lymphoproliferative Disorders; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Risk; Severity of Illness Index; Thrombopoietin | 2014 |
Recent developments in drug therapy for aplastic anemia.
Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Clinical Trials as Topic; Cyclosporine; Daclizumab; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Pyrazoles; Recurrence; Salvage Therapy; Survival Rate | 2014 |
[Recent progress in the management of aplastic anemia].
Topics: Acute Disease; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Chronic Disease; Cyclosporine; Disease Progression; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2014 |
[Aplastic anemia].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning | 2014 |
Eltrombopag in aplastic anemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Hematopoiesis; Humans; Hydrazines; Pyrazoles; Recurrence; Risk Factors; Thrombopoietin | 2015 |
Eltrombopag: a review of its use in patients with severe aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Hematinics; Hematopoiesis; Humans; Hydrazines; Practice Guidelines as Topic; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2015 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Eltrombopag for the treatment of aplastic anemia: current perspectives.
Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Cyclophosphamide; Cyclosporine; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2016 |
Nontransplant therapy for bone marrow failure.
Topics: Anemia, Aplastic; Anemia, Refractory; Benzoates; Danazol; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles | 2016 |
15 trial(s) available for hydrazine and Anemia, Aplastic
Article | Year |
---|---|
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Topics: Adult; Anemia, Aplastic; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Survival Analysis; Treatment Outcome; Young Adult | 2022 |
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Young Adult | 2022 |
Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; East Asian People; Humans; Hydrazines; Immunosuppressive Agents; Prospective Studies; Treatment Outcome | 2023 |
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles | 2020 |
Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Child, Preschool; Cyclosporine; Female; Follow-Up Studies; Humans; Hydrazines; Immunosuppressive Agents; Male; Off-Label Use; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2020 |
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Japan; Neoplasm Recurrence, Local; Pyrazoles; Treatment Outcome | 2021 |
Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Treatment Outcome | 2021 |
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antigens, CD34; Antilymphocyte Serum; Benzoates; Cell Count; Cyclosporine; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2017 |
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Immunosuppression Therapy; Male; Middle Aged; Platelet Count; Pyrazoles; Severity of Illness Index; Thrombopoietin; Time Factors | 2018 |
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.
Topics: Anemia, Aplastic; Benzoates; Clonal Evolution; Female; Humans; Hydrazines; Male; Pyrazoles | 2019 |
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Blood Transfusion; Cell Lineage; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Drug Resistance; Drug Substitution; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Japan; Male; Middle Aged; Pharyngitis; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2019 |
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow; Clonal Evolution; Female; Hematologic Agents; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2014 |
[Thrombopoietin receptor agonist arouses new hope].
Topics: Anemia, Aplastic; Benzoates; Drug Approval; Hematopoietic Stem Cells; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow Cells; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Young Adult | 2012 |
61 other study(ies) available for hydrazine and Anemia, Aplastic
Article | Year |
---|---|
[Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Thrombopoietin | 2021 |
Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Cell Proliferation; Dioxygenases; DNA-Binding Proteins; Hematopoietic Stem Cells; Humans; Hydrazines; Mice; Mice, Knockout; Pyrazoles | 2022 |
Changes in bone marrow and peripheral blood lymphocyte subset findings with onset of hepatitis-associated aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Cytomegalovirus Infections; Hepatitis; Humans; Hydrazines; Infant; Killer Cells, Natural; Lymphocyte Subsets; Lymphocytes; Male; Pyrazoles; Receptors, Thrombopoietin | 2022 |
Long-term eltrombopag for bone marrow failure depletes iron.
Topics: Anemia, Aplastic; Benzoates; Ferritins; Humans; Hydrazines; Iron; Iron Overload; Pancytopenia; Pyrazoles; Recurrence; Thrombocytopenia | 2022 |
[The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies | 2022 |
[Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag].
Topics: Adult; Anemia, Aplastic; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles | 2022 |
Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Treatment Outcome; Young Adult | 2022 |
Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
Topics: Anemia, Aplastic; Animals; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Siblings; Swine | 2022 |
An eltrombopag-induced remission of bone-marrow aplasia accompanied by marked leukoerythroblastosis and splenomegaly.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Humans; Hydrazines; Pyrazoles; Splenomegaly | 2022 |
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia.
Topics: Anemia, Aplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Camptothecin; Cytochrome P-450 CYP2C8; Genotype; Glucuronosyltransferase; Humans; Hydrazines; Neoplasm Proteins; Polymorphism, Genetic; Pyrazoles | 2022 |
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
Topics: Adult; Anemia, Aplastic; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Prospective Studies; Pyrazoles; Retrospective Studies; Treatment Outcome | 2022 |
A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; China; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2022 |
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Retrospective Studies | 2023 |
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
Topics: Adult; Age Factors; Aged; Anemia, Aplastic; Antineoplastic Agents; Benzoates; Comorbidity; Female; Health Expenditures; Health Resources; Hospitalization; Humans; Hydrazines; Insurance Claim Review; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazoles; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors | 2020 |
Distinctive and common features of moderate aplastic anaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult | 2020 |
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Boston; Combined Modality Therapy; Cost of Illness; Drug Resistance; Female; Follow-Up Studies; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Paris; Pyrazoles; Retrospective Studies; Sample Size; Young Adult | 2020 |
Deficit of circulating CD19
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Benzoates; Bone Marrow; CD24 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Interleukin-10; Killer Cells, Natural; Lymphocyte Count; Lymphopenia; Male; Membrane Glycoproteins; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2020 |
Disappearance of monosomy 7 in a patient with aplastic anemia after eltrombopag treatment.
Topics: Aged; Anemia, Aplastic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 7; Female; Humans; Hydrazines; Pyrazoles | 2020 |
[Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2019 |
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening | 2020 |
High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Prognosis; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Retrospective Studies; Thrombopoietin; Young Adult | 2021 |
An Eltrombopag Red (Plasma) Alert.
Topics: Anemia, Aplastic; Benzoates; Bilirubin; Female; Humans; Hydrazines; Middle Aged; Plasma; Pyrazoles | 2021 |
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Anemia, Refractory; Benzoates; Drug Substitution; Drug Tolerance; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; China; Female; Follow-Up Studies; Hospitals, University; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2020 |
Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency.
Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Common Variable Immunodeficiency; Cyclosporine; Exome Sequencing; Female; Genetic Predisposition to Disease; Haploinsufficiency; Humans; Hydrazines; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Pyrazoles; Signal Transduction | 2020 |
Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD34; Benzoates; Biopsy, Needle; Bone Marrow Cells; Brazil; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Multipotent Stem Cells; Pyrazoles; Receptors, Thrombopoietin | 2021 |
Paediatric severe aplastic anaemia treatment: where to start?
Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles | 2021 |
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Eruptions; Female; Gingival Hypertrophy; Hirsutism; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Retrospective Studies; Tacrolimus | 2021 |
Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Rabbits; Retrospective Studies; Treatment Outcome | 2021 |
Eltrombopag in children with severe aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Treatment Outcome | 2021 |
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Retrospective Studies; Young Adult | 2022 |
Role of eltrombopag in severe aplastic anemia treatment in children.
Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Pyrazoles | 2021 |
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Topics: Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2018 |
Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Topics: Adult; Anemia, Aplastic; Benzoates; Biomarkers; Combined Modality Therapy; Disease Management; Drug Resistance; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Recurrence; Thrombopoietin; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors.
Topics: Anemia, Aplastic; Benzoates; Case-Control Studies; Cell Differentiation; Cell Line; Cell Proliferation; Colony-Forming Units Assay; Fibroblasts; Hematopoietic Stem Cells; Humans; Hydrazines; Induced Pluripotent Stem Cells; Models, Biological; Pyrazoles; Telomerase; Telomere; Telomere Shortening | 2018 |
Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Middle Aged; Pyrazoles; Severity of Illness Index | 2018 |
Eltrombopag mobilizes iron in patients with aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Biomarkers; Humans; Hydrazines; Iron; Pyrazoles; Treatment Outcome | 2018 |
[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2019 |
Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Male; Pyrazoles; Remission Induction | 2018 |
Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
Topics: Adult; Anemia, Aplastic; Benzoates; Color; Female; Gene Expression; Humans; Hydrazines; Hyperpigmentation; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index | 2019 |
Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Gaucher Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Thrombocytopenia; Thrombopoietin | 2019 |
Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Aptamers, Nucleotide; Benzoates; Biomarkers; Blood Proteins; Child; Child, Preschool; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Molecular Targeted Therapy; Proteomics; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2018 |
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Biomarkers; Biopsy; Bone Marrow; Humans; Hydrazines; Molecular Targeted Therapy; Prognosis; Pyrazoles; Treatment Outcome | 2019 |
Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Middle Aged; Pyrazoles; Uterine Hemorrhage | 2019 |
Use of eltrombopag in aplastic anemia in Europe.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Evaluation; Drug Utilization; Europe; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult | 2019 |
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.
Topics: Adult; Aged; Anemia, Aplastic; Anti-Bacterial Agents; Antilymphocyte Serum; Benzoates; Biodiversity; Cyclosporine; Dental Health Surveys; DNA, Bacterial; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunocompromised Host; Immunosuppressive Agents; Male; Microbiota; Middle Aged; Mouth; Pilot Projects; Pyrazoles; Ribotyping; Sequence Analysis, DNA; Smoking; T-Lymphocytes; Tongue; Young Adult | 2019 |
A rare side effect: eltrombopag associated hyperpigmentation.
Topics: Aged; Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Melanosis; Pyrazoles | 2020 |
Management of acquired aplastic anemia in children : A single center experience.
Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Levamisole; Male; Pyrazoles; Retrospective Studies | 2019 |
Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
Topics: Anemia, Aplastic; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Iron; Male; Prospective Studies; Pyrazoles | 2019 |
Eltrombopag: wielding a double-edged sword?
Topics: Anemia, Aplastic; Benzoates; Genomics; Humans; Hydrazines; Pyrazoles | 2019 |
Eltrombopag: a stem cell cookie?
Topics: Anemia, Aplastic; Benzoates; Female; Hematopoiesis; Humans; Hydrazines; Male; Pyrazoles | 2014 |
Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.
Topics: Aged; Anemia, Aplastic; Benzoates; HIV Infections; Humans; Hydrazines; Immunologic Factors; Male; Pyrazoles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells | 2014 |
Eltrombopag interference in routine chemistry testing.
Topics: Anemia, Aplastic; Artifacts; Benzoates; Blood Chemical Analysis; Cholesterol; Female; Humans; Hydrazines; Middle Aged; Phosphates; Pyrazoles; Thrombocytopenia; Triglycerides | 2016 |
Supportive Care and Newer Therapies in Aplastic Anaemia.
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Opportunistic Infections; Prognosis; Pyrazoles; Secondary Prevention | 2015 |
Guidelines for the diagnosis and management of adult aplastic anaemia.
Topics: Aged; Anemia, Aplastic; Benzoates; Blood Component Transfusion; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Opportunistic Infections; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Severity of Illness Index | 2016 |
The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2017 |
Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Topics: Adult; Anemia, Aplastic; Back; Benzoates; Drug Eruptions; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2016 |
A promising new treatment for refractory aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles | 2012 |
Eltrombopag in refractory aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles | 2012 |
Eltrombopag in refractory aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles | 2012 |
[The results of attack polychemotherapy in broncho-pleuro-pulmonary cancer. Phytohemagglutinin in the prevention and treatment of hematologic complications of antimitotics].
Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Pleural Neoplasms; Vinblastine | 1968 |